Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Outcomes-Based Reimbursement Experiment

Executive Summary

US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.


Related Content

Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines
Expect Industry To Step Up Drug Pricing Self-Regulation In 2017 – PwC
US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
Merck/Aetna Pact Links Januvia Value-Based Payment To Treatment Intensification
Lilly's Performance Contract For Trulicity Hinges On Head-To-Head Superiority
UnitedHealth Moving, Slowly, Toward More Value-Based Drug Contracts
Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume
Industry's Rebate Arms Race: Securing Market Access At A Cost


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts